Diabetic Nephropathy | Treatment Algorithms: Claims Data Analysis | US | 2024

Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs intended to halt the progression of kidney damage associated with diabetes. In a landmark renal outcomes trial, Invokana emerged as the first antidiabetic medication to exhibit a renoprotective effect, evidenced by a substantial reduction in the relative risk of a renal-specific composite endpoint. This breakthrough has paved the way for the broader use of the SGLT-2 inhibitor class to lower eGFR limits, potentially transforming treatment approaches in this field. In 2021, Bayer’s Kerendia became the first FDA-approved mineralocorticoid receptor antagonist specifically designed to slow the progression of DN. Moreover, the adoption of GLP-1 receptor agonists and dual GLP-1 / GIP receptor agonists is gaining momentum in the DN treatment paradigm. These classes of drugs, known for their glucose-lowering effects, are now being recognized for their potential benefits in managing DN, further enriching the therapeutic options for patients with this complex disease.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed DN patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed DN patients?
• How have SGLT-2 inhibitors, GLP-1 receptor agonists, GLP 1 / GIP receptor agonists, and Kerendia been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of DN patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
• What percentage of DN patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies AstraZeneca, Bayer, Johnson and Johnson, Novo Nordisk, Eli Lilly

Key drugs: Metformin, Kerendia, Farxiga, Jardiance, Mounjaro, Ozempic, Byetta, Glyxambi

KEY FEATURE

Dashboard featuring interactive visuals, easy navigation, and expanded analyses